Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642909 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Dec 2027 to Mar 31, 2027
    • Study completion date: Dec 2027 to May 10, 2027
    • Start date changed from estimate of Oct 2024 to Nov 13, 2024
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, sample size, and endpoint evaluation time
Trial Details
NCT Number NCT06642909
Lead Sponsor BioRay Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Primary Membranous Nephropathy
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov